0001104659-23-084992.txt : 20230728 0001104659-23-084992.hdr.sgml : 20230728 20230728061930 ACCESSION NUMBER: 0001104659-23-084992 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20230727 FILED AS OF DATE: 20230728 DATE AS OF CHANGE: 20230728 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: KOVEN ANDREW I CENTRAL INDEX KEY: 0001258673 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37809 FILM NUMBER: 231120115 MAIL ADDRESS: STREET 1: 3 COLUMBUS CIRCLE, SUITE 1710 STREET 2: C/O ARALEZ PHARMACEUTICALS INC. CITY: NEW YORK STATE: NY ZIP: 10019 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NeuroBo Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001638287 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 472389984 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 BERKELEY ST. STREET 2: FL 19 CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: (857) 702-9600 MAIL ADDRESS: STREET 1: 200 BERKELEY ST. STREET 2: FL 19 CITY: BOSTON STATE: MA ZIP: 02116 FORMER COMPANY: FORMER CONFORMED NAME: Gemphire Therapeutics Inc. DATE OF NAME CHANGE: 20150331 4 1 tm2321997-2_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2023-07-27 0 0001638287 NeuroBo Pharmaceuticals, Inc. NRBO 0001258673 KOVEN ANDREW I C/O NEUROBO PHARMACEUTICALS, INC. 200 BERKELEY STREET, OFFICE 19TH FLOOR BOSTON MA 02116 1 0 0 0 0 Common Stock 2023-07-27 4 A 0 87500 0 A 87500 D Common Stock 2023-07-27 4 A 0 12500 0 A 100000 D Represents a grant of restricted stock units ("RSUs") issued to the reporting person under the Issuer's 2022 Equity Incentive Plan. Per the terms of the Amended and Restated Non-Employee Director Compensation Policy, the reporting person elected to defer receipt of the shares of common stock upon the vesting of the RSUs until the earlier of the date that is (i) immediately prior to a Change in Control (as described in the Policy), or (ii) within 60 days following the reporting person's retirement or other separation form service with the Issuer or death, whichever is earlier. 50% of the RSUs vested immediately, and the remainder will vest in two equal installments on each subsequent anniversary of the date of grant, subject to continuing service. Vests on the earlier of July 27, 2024 or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to continuing service. Exhibit 24, Power of Attorney, is attached. /s/ Phillip D. Torrence, by Power of Attorney 2023-07-28 EX-24 2 tm2321997-2_ex24.htm EXHIBIT 24

 

Exhibit 24

 

POWER OF ATTORNEY

 

Know all men by these presents, that the undersigned hereby constitutes and appoints each of Adam Perlish, Phillip D. Torrence and Jeffrey Kuras, signing singly, and with full power of substitution, his or her true and lawful attorney-in-fact to:

 

(1)execute for and on behalf of the undersigned, with respect to the undersigned's position as an officer and/or director of NeuroBo Pharmaceuticals, Inc. (the “Company”), Form ID and Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;

 

(2)do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form ID or Forms 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the United States Securities and Exchange Commission and any stock exchange, stock market or similar authority; and

 

(3)take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, and in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

 

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

 

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

 

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 10th day of June, 2022.

 

 /s/ Andrew I. Koven
  Andrew I. Koven